drugset / Trial / NCT00847834

Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population

NCT00847834

Phase 4 Completed 968 enrolled Sanofi
Parallel-groupOpen-labelTreatment

Summary

To analyse the control rate of irbesartan/hydrochlorothiazide(HCTZ) (COAPROVEL) in the treatment of patients with mild to moderate primary hypertension.

Timeline

Start
2003-12
Primary completion
2004-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 12.5 mg
Subject Irbesartan Small molecule 150 mg